Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Phase 3 trials have shown that nintedanib reduces the decline in forced vital capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with acceptable safety profiles; however, its effects on advanced IPF are unclear. We investigated the efficacy and safety of nintedanib in patients with advanced IPF.Prospective data were obtained from 108 IPF patients administered at least one dose of nintedanib. Of these patients,...